Zelda Therapeutics has been formed to bring together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.
We believe that by investing in rigorous research and clinical trials we can generate significant value for all stakeholders as the world re-acquaints itself with this ancient medicine.
Richard is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters.During his career, Dr. Hopkins has managed and overseen several strategic alliance and licensing deals with multiple global pharmaceutical partners.
Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company. Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.
Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr. Hopkins currently serves as Chair of the Western Australian Ausbiotech Committee.
Harry graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States. He has in excess of 23 years diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing and has acted as a Director on several public and private companies in Australia, Singapore and the United Kingdom. Harry resides in Australia.
Mara Gordon – Founder, Aunt Zelda's, Calla Spring Wellness, and Zelda Therapeutics. Mara specializes in the development of treatment protocols utilizing Bio Pharmaceutical grade cannabis extracts for seriously ill patients in California. She co-founded Aunt Zelda's, Calla Spring Wellness, and Zelda Therapeutics in order to provide real outcomes for patients with serious diseases. Prior to Aunt Zelda's, Mara worked as a process engineer, helping Fortune 500 companies create intelligent software by utilizing the Rational Unified Process. This experience has enabled her to take a detailed and scientific approach to utilizing cannabis as a Biopharmaceutical-grade treatment. Gordon sits on the boards of Zelda Therapeutics, Daya Foundation, International Cannabis Standards Board (ICSB), and Hmbldt. She has presented at multiple CME-accredited medical conferences, including Patients Out of Time 2014, 2016, delivered 3.5 hour courses along with Drs. Cristina Sanchez, Manuel Guzman, Donald Abrams, and Joe D. Goldstrich. Gordon has spoken at medical cannabis conferences in Australia, Costa Rica, Chile, Colombia, the Czech Republic, Israel, as well as numerous events throughout the USA and worldwide. These include CannMed held at Harvard Medical School in April 2016, CannaTech in Israel, and Medical Marijuana for Professionals 2014 and 2016 in CO. Her work is featured in the upcoming documentaries, “Weed the People”, “Mary Janes: Women of Weed”, and in Joe Dolce’s book, “Brave New Weed”. Mara resides in California.
Jason is a Director, major shareholder and Head of Corporate of boutique stock broking and corporate advisory firm, CPS Capital. He has more than 19 years experience in the financial advisory sector, which he obtained by working in both local and international stockbroking companies such as Patersons, Tolhurst, and Merrill Lynch. He specialises in corporate structuring, capital raisings, corporate and strategic advice to small and medium size companies and reverse takeovers. He holds a Bachelor of Commerce degree from Curtin University and a Graduate Diploma of Finance from FINSIA (Financial Services Institute of Australia)/SDIA (Securities & Derivatives Institute of Australia). Jason resides in Australia.
Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently Chairman of ASX-listed Orthocell Ltd (culturing tendon cells to repair damaged tendons) and Cynata Therapeutics Ltd (developing stem cell therapies) and Chairman of privately-held Minomic International Ltd (accurate non-invasive test for prostate cancer). Stewart has held several past senior executive roles including CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. Stewart resides in Australia.
Professor Guzmán is the Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University. His PhD and postdoctoral research focused on the study of the regulation of liver and brain lipid metabolism. During the last twenty years he has been mostly involved in the study of how cannabinoids act in the body, with special emphasis on the molecular mechanisms of that action and on understanding how cannabinoids control cell generation and death. This work has allowed characterizing new effects and signalling pathways evoked by cannabinoids, as well as putting forward new physiopathological implications derived from them. Dr. Guzman has published 136 articles and 7 patents and supervised 15 PhD thesis. He has been Secretary of the SEBBM (2006-2010) and founder and secretary of the Spanish Society for Cannabinoids Research (SEIC) where he is the current President. He is also an Academic Member of The Royal National Academy of Pharmacy (Spain) as well as a member of the Board of Directors of the International Association for Cannabinoid Medicines (IACM). Professor Guzman resides in Spain.
Dr Sánchez is an Associate Professor of Biochemistry and Molecular Biology and Vice Dean of Research of the School of Biology. Her PhD and postdoctoral training were focused on lipid signaling, including that of cannabinoids in an oncology setting. The goal of her current research is to understand and exploit cannabinoids as potential antitumoral agents in breast cancer. More recently, she has also focused her attention on new cannabinoid receptors and their possible involvement in cannabinoid antitumoral action in breast cancer and other type of tumors. She has been Secretary of the Spanish Cannabinoid Research Society (2011-2015) and is one of the founders and Secretary of the Spanish Observatory on Medicinal Cannabis. Dr Sanchez resides in Spain.
Dr Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles), part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre. He specialises in treating children, adolescents and young adults with these aggressive cancers. He runs a comprehensive and multidisciplinary program involving paediatric and medical oncologists, radiation oncologists, orthopaedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists.
Dr Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Dr Federman received a BA in English Literature and minor in neuroscience at Williams College, Massachusetts. He received a Medical Doctorate Degree from the Mount Sinai School of Medicine- New York University, New York and completed his residency and fellowship training in Pediatric Hematology/Oncology at the University of California, Los Angeles. He is now a full-time member of the faculty at UCLA.
As a member of the Scientific Advisory Board Dr Federman will be instrumental in shaping the rigorous scientific research and clinical trials that Zelda plans to fund as part of its strategy to become a leading biotechnology company in the emerging medical cannabis sector.
Amanda has over 15 years experience working in the alcohol and other drug sector for government and non-government entities across Australia. At the Australian Institute of Health and Welfare (AIHW) she managed the data and reporting of national data sets for a range of health publications after spending two years in far north Queensland, delivering alcohol-related health education campaigns to Aboriginal communities. In roles ranging from direct client service delivery to senior policy advisor, she completed a Master of Public Health, majoring in Harm Reduction, while leading statewide campaigns on methamphetamine and implementing amendments to the Drugs, Poisons and Controlled Substances Act.
Nicole is an experienced and driven marketing and communications executive, with over 15 years’ experience working across government and industry. Her diverse experience includes a science background, having a Bachelor of Science (Hons) in Biotechnology, followed by extensive experience in government, trade and marketing roles, including senior advisory roles to Ministers for developing and implementing policy on various issues ranging from food safety to biotechnology regulation. Nicole sits on a number of company Boards and is Director of her own marketing and communications company. Nicole is an advisor to Zelda Therapeutics assisting with communications and business development activities.